Shares of Neos Therapeutics Inc. (NASDAQ:NEOS) traded up 2.8% during mid-day trading on Friday . The company traded as high as $7.09 and last traded at $7.03, with a volume of 80,456 shares traded. The stock had previously closed at $6.84.

A number of analysts have recently issued reports on the stock. BMO Capital Markets assumed coverage on shares of Neos Therapeutics in a report on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price objective for the company. Royal Bank Of Canada decreased their target price on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 17th. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Neos Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.75.

The firm’s market cap is $112.17 million. The company has a 50-day moving average price of $8.57 and a 200 day moving average price of $9.50.

Neos Therapeutics (NASDAQ:NEOS) last announced its earnings results on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. On average, equities analysts forecast that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current year.

In other news, insider Juergen Martens acquired 10,000 shares of Neos Therapeutics stock in a transaction dated Monday, June 13th. The stock was purchased at an average cost of $9.90 per share, with a total value of $99,000.00. Following the completion of the purchase, the insider now directly owns 10,000 shares in the company, valued at approximately $99,000. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP boosted its position in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 as of its most recent SEC filing.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).